Interim Report January - March 2014

CONTINUED STRONG SALES GROWTH AND REGULATORY SUCCESSES WITH XPS™ AND STEEN
SOLUTION™
FIRST QUARTER 2014 (JAN – MAR)

• Net sales in the quarter amounted to SEK 18.3 (16.3) million, corresponding to
an increase of 12 percent in SEK. Sales increased by 10 percent in local
currency.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK
3.1 (3.8) million, corresponding to an EBITDA margin of 17 percent.

• Net income amounted to SEK 1.8 (2.4) million, resulting in earnings per share
of SEK 0.09 (0.12).

• Cash flow from operating activities was SEK -3.3 (4.0) million due to changes
in trade payables that amounted to SEK -3.6 million and paid taxes that amounted
to SEK -2.6 million.

• STEEN Solution™ and related products accounted for 24 (16) percent of total
sales.

• The Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0,
that the XPS™ System with STEEN Solution™ meets the requirements for HDE
(Humanitarian Device Exemption) approval.

• XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the
accompanying single-use products to be sold in Europe.

• The first lung transplant in Turkey using a lung treated with the STEEN
Solution™ method was performed at Sureyyapasa Teaching Hospital.

• Barnes Jewish Hospital in St. Louis, which is a pioneer in lung
transplantation, will be the tenth transplant center to participate in the NOVEL
trial. Organ Procurement Organization* (OPO) Mid-America Transplant Services in
Missouri has bought an XPS™ to strengthen the collaboration between transplant
centers and OPOs. The company plans to continue deploying XPS™ with recovery of
costs, at transplant centers in the United States during the second quarter.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on
Friday, April 23, 2014. Telephone: +46 8 50336434, enter code 1319928

April 23, 2014
Gothenburg

XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

** An OPO or Organ Procurement Organization is responsible for coordination and
assessment of donated organs for organ transplantation in a region in the US.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
23, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com